晚期肝细胞癌的随机试验与终点:无进展生存期作为生存替代指标的作用
综述分析了21项晚期肝细胞癌III期试验,发现无进展生存期(PFS)与总生存期(OS)中度相关(R=0.84),但7项研究中PFS显著改善仅3项与OS改善相关,且这些病例PFS的风险比(HR)≤0.6,提示PFS的HR≤0.6可作为OS的潜在替代终点,而HR 0.6-0.7为不确定替代。
要点
- 21项III期试验中PFS与OS中度相关(R=0.84),TTP与OS相关(R=0.83)。
- 7项PFS显著改善的研究仅3项OS也显著改善,这些病例PFS的HR≤0.6。
- PFS的HR在0.6-0.7之间虽显著但未与生存获益相关,视为不确定替代。
核心结论
- PFS的HR≤0.6可作为晚期肝细胞癌OS的潜在替代终点,而HR 0.6-0.7为不确定替代。
研究设计与样本
- 综述分析21项晚期肝细胞癌III期随机试验,评估PFS、TTP和客观缓解率(ORR)作为生存替代终点的优势与局限。
主要发现
- 21项III期试验中PFS与OS相关系数R=0.84,TTP与OS相关系数R=0.83。
- 7项III期研究中PFS显著差异仅3项与OS差异相关,这些病例PFS的HR≤0.6。
- PFS的HR在0.6-0.7之间虽显著但未与更好生存相关,视为不确定替代。
关键数值与推荐
- PFS的HR≤0.6被提出作为晚期肝细胞癌OS的潜在替代终点。
- PFS的HR在0.6-0.7之间被视为不确定替代终点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide. Around half of patients with HCC will receive systemic therapies during their life span. The pivotal positive sorafenib trial and regulatory approval in 2007 was followed by a decade of negative studies with drugs leading to marginal antitumoral efficacy, toxicity, or trials with a lack of enrichment strategies. This trend has changed over the last 2 years with several compounds, such as lenvatinib (in first-line) and regorafenib, cabozantinib, ramucirumab and nivolumab (in second-line), showing clinical benefit. These successes came at a cost of increasing the complexity of decision-making, and ultimately, impacting the design of future clinical trials. Nowadays, life expectancy with single active agents has surpassed the threshold of 1 year and sequential strategies have provided encouraging outcomes. Overall survival (OS) remains the main endpoint in phase III investigations, but as in other solid tumours, there is a clear need to define surrogate endpoints that both reliably recapitulate survival benefits and can be assessed before additional efficacious drugs are administered. A thorough analysis of 21 phase III trials published in advanced HCC demonstrated a moderate correlation between progression-free survival (PFS) or time to progression (TTP) and OS (R = 0.84 and R = 0.83, respectively). Nonetheless, the significant differences in PFS identified in 7 phase III studies only correlated with differences in OS in 3 cases. In these cases, the hazard ratio (HR) for PFS was ≤0.6. Thus, this threshold is herein proposed as a potential surrogate endpoint of OS in advanced HCC. Conversely, PFS with an HR between 0.6-0.7, despite significance, was not associated with better survival, and thus these magnitudes are considered uncertain surrogates. In the current review, we discuss the reasons for positive or negative phase III trials in advanced HCC, and the strengths and limitations of surrogate endpoints (PFS, TTP and objective response rate [ORR]) to predict survival.
引用
- Llovet JM, Montal R, Villanueva A, et al. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. J Hepatol. 2019. PMID: 30943423. doi:10.1016/j.jhep.2019.01.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。